Exact Sciences, a molecular diagnostics company, has acquired genetic testing laboratory PreventionGenetics to enhance its cancer diagnostics portfolio and to support its entry into the hereditary cancer testing market. The deal took place for a total consideration of USD 190 million, with 50% paid out in cash and 50% in Exact common stock. 

The acquisition will allow Exact Sciences to leverage PreventionGenetics’ laboratory and capabilities in sequencing, informatics, and genetic counseling to support its entry into hereditary cancer testing across the US and internationally. 

PreventionGenetics is a Clinical Laboratory Improvement Amendments (CLIA)-certified and a Collage of American Pathologists (CAP)-accredited clinical genetic testing laboratory that provides more than 5,000 predefined tests including custom panels as well a germline whole exome and whole genome sequencing tests covering areas such as cancer risk, pediatric and adult rare diseases, and proactive care. The company’s revenue for 2021 was estimated to be USD 36 million and its adjusted EBITDA was expected to reach USD 3 million for the year. 

Wisconsin-based Exact Sciences specializes in providing cancer screening and genetic testing for ​​colorectal cancer using stool-based DNA (sDNA) technology. The company also offers testing for breast cancer and prostate cancer. More than 300,000 healthcare providers and 200 hospitals currently use its Cologuard and Oncotype genetic tests.